TYVASO is indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.1

The study establishing effectiveness predominately included patients with etiologies of1:

  • Idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF)
  • Combined pulmonary fibrosis and emphysema (CPFE) (25%)
  • WHO Group 3 connective tissue disease (22%)

The study establishing effectiveness predominately included patients with etiologies of1:

  • Idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF)
  • Combined pulmonary fibrosis and emphysema (CPFE) (25%)
  • WHO Group 3 connective tissue disease (22%)

Request a Rep

To have a United Therapeutics Cardiopulmonary Specialist contact you about TYVASO for PH-ILD, please fill out the form below and click Submit.

*Required field

Privacy

United Therapeutics respects your right to have your personal information kept private. We may use this information to send you materials on our products and services that may be of interest to you. We will not share your information with any third parties or outside mailing lists.

Clicking the Submit button signifies that you have read and agree to our Privacy Policy, and that you agree to receive future communications from Tyvaso.com or United Therapeutics Corporation.